

Christine Desmedt

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4896413/christine-desmedt-publications-by-year.pdf>
Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

169 papers	20,639 citations	49 h-index	143 g-index
232 ext. papers	24,715 ext. citations	7.7 avg, IF	5.7 L-index

#	Paper	IF	Citations
169	Abstract PD14-05: Portraying tumor evolution of lobular breast cancer through phylogenetic analysis. <i>Cancer Research</i> , 2022 , 82, PD14-05-PD14-05	10.1	
168	Abstract P1-02-09: Results of a worldwide survey on the currently used histopathological diagnostic criteria for invasive lobular breast cancer (ILC). <i>Cancer Research</i> , 2022 , 82, P1-02-09-P1-02-09	10.1	
167	Abstract P3-09-18: The association between genomic alterations and body mass index in patients with early breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-09-18-P3-09-18	10.1	
166	Abstract P4-02-02: The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer. <i>Cancer Research</i> , 2022 , 82, P4-02-02-P4-02-02	10.1	
165	Abstract P3-08-07: Comparison of the genomic alterations in metastatic inflammatory and non-inflammatory breast cancer. <i>Cancer Research</i> , 2022 , 82, P3-08-07-P3-08-07	10.1	
164	Loss of E-cadherin leads to Id2-dependent inhibition of cell cycle progression in metastatic lobular breast cancer.. <i>Oncogene</i> , 2022 ,	9.2	2
163	Spatial interplay of lymphocytes and fibroblasts in estrogen receptor-positive HER2-negative breast cancer.. <i>Npj Breast Cancer</i> , 2022 , 8, 56	7.8	1
162	Tumor Infiltrating Lymphocytes in Breast Cancer: Implementation of a New Histopathological Biomarker 2022 , 207-243		1
161	Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021 , 191, 451	4.4	1
160	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 462-470	9.7	6
159	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. <i>Npj Breast Cancer</i> , 2021 , 7, 31	7.8	2
158	A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer. <i>Nature Medicine</i> , 2021 , 27, 820-832	50.5	57
157	Correlation of Trop-2 expression with clinicopathological characteristics, sTILs, AR expression and outcome in primary TNBC.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e12558-e12558	2.2	1
156	The genomic landscape of carcinomas with mucinous differentiation. <i>Scientific Reports</i> , 2021 , 11, 9478	4.9	1
155	How Researchers, Clinicians and Patient Advocates Can Accelerate Lobular Breast Cancer Research. <i>Cancers</i> , 2021 , 13,	6.6	2
154	Downregulation of the FTO mA RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.. <i>Nature Cancer</i> , 2021 , 2, 611-628	15.4	2
153	Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 146-153	9.7	11

152	Body Mass Index and Weight Change in Patients With HER2-Positive Early Breast Cancer: Exploratory Analysis of the ALTTO BIG 2-06 Trial. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 181-189	7.3	3
151	Does Physical Activity Have an Impact on Recurrence Dynamics in Early Breast Cancer Patients?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	5
150	Comparison of the tumor immune microenvironment of primary hormone receptor-negative HER2-positive and triple negative breast cancer. <i>Npj Breast Cancer</i> , 2021 , 7, 128	7.8	0
149	Is cancer biology different in older patients?. <i>The Lancet Healthy Longevity</i> , 2021 , 2, e663-e677	9.5	5
148	Inter-observer agreement for the histological diagnosis of invasive lobular breast carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2021 ,	5.3	2
147	Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer. <i>Breast</i> , 2020 , 52, 64-70	3.6	4
146	MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. <i>Cancers</i> , 2020 , 12,	6.6	11
145	Abstract P3-01-13: Association between the histopathological growth patterns (HGP) of liver metastases (LM) and survival after hepatic surgery in patients with oligometastatic breast cancer (BC) 2020 ,		2
144	Metastasis by semi-quantitative oestrogen receptor expression in stage I-III early diagnosed triple positive breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2020 , 38, e13031-e13031	2.2	
143	Association between the histopathological growth patterns of liver metastases and survival after hepatic surgery in breast cancer patients. <i>Npj Breast Cancer</i> , 2020 , 6, 64	7.8	7
142	Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 708-719	9.7	45
141	Phylogenetic reconstruction of breast cancer reveals two routes of metastatic dissemination associated with distinct clinical outcome. <i>EBioMedicine</i> , 2020 , 56, 102793	8.8	10
140	Digital analysis of distant and cancer-associated mammary adipocytes. <i>Breast</i> , 2020 , 54, 179-186	3.6	1
139	Characterization of Stromal Tumor-infiltrating Lymphocytes and Genomic Alterations in Metastatic Lobular Breast Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 6254-6265	12.9	10
138	Assessment of stromal tumor infiltrating lymphocytes and immunohistochemical features in invasive micropapillary breast carcinoma with long-term outcomes. <i>Breast Cancer Research and Treatment</i> , 2020 , 184, 985-998	4.4	5
137	The circular RNome of primary breast cancer. <i>Genome Research</i> , 2019 , 29, 356-366	9.7	55
136	Microscopic tumor foci in axillary lymph nodes may reveal the recurrence dynamics of breast cancer. <i>Cancer Communications</i> , 2019 , 39, 35	9.4	2
135	A key genomic subtype associated with lymphovascular invasion in invasive breast cancer. <i>British Journal of Cancer</i> , 2019 , 120, 1129-1136	8.7	12

134	Tumor characteristics and outcome by androgen receptor expression in triple-negative breast cancer patients treated with neo-adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019 , 176, 699-708	4.4	13
133	Tumor dormancy at bedside: A late awakening. <i>Breast</i> , 2019 , 45, 61-63	3.6	6
132	Genomic, Transcriptomic, Epigenetic, and Immune Profiling of Mucinous Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 742-746	9.7	10
131	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 69-77	9.7	40
130	mutations in metastatic lobular breast cancer patients. <i>Npj Breast Cancer</i> , 2019 , 5, 9	7.8	15
129	Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 25	8.3	20
128	Comprehensive evaluation of methods to assess overall and cell-specific immune infiltrates in breast cancer. <i>Breast Cancer Research</i> , 2019 , 21, 151	8.3	14
127	Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. <i>Oncogene</i> , 2019 , 38, 2814-2829	9.2	45
126	Immune Infiltration in Invasive Lobular Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2018 , 110, 768-776	9.7	55
125	A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2018 , 29, 162-169	10.3	26
124	Breast cancer diagnosed during pregnancy is associated with enrichment of non-silent mutations, mismatch repair deficiency signature and mucin mutations. <i>Npj Breast Cancer</i> , 2018 , 4, 23	7.8	12
123	Impact of body mass index (BMI) and weight change after treatment in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Secondary analysis of the ALTTO BIG 2-06 trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 10067-10067	2.2	2
122	Circulating tumor DNA in early response assessment and monitoring of advanced colorectal cancer treated with a multi-kinase inhibitor. <i>Oncotarget</i> , 2018 , 9, 17756-17769	3.3	21
121	Transcriptomic and genomic features of invasive lobular breast cancer. <i>Seminars in Cancer Biology</i> , 2017 , 44, 98-105	12.7	20
120	Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. <i>Nature Communications</i> , 2017 , 8, 14944	17.4	79
119	Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer. <i>Modern Pathology</i> , 2017 , 30, 1204-1212	9.8	50
118	Recurrence dynamics of breast cancer according to baseline body mass index. <i>European Journal of Cancer</i> , 2017 , 87, 10-20	7.5	27
117	Genomic Evolution of Breast Cancer Metastasis and Relapse. <i>Cancer Cell</i> , 2017 , 32, 169-184.e7	24.3	346

116	The AURORA pilot study for molecular screening of patients with advanced breast cancer-a study of the breast international group. <i>Npj Breast Cancer</i> , 2017 , 3, 23	7.8	5
115	DNA methylation-based immune response signature improves patient diagnosis in multiple cancers. <i>Journal of Clinical Investigation</i> , 2017 , 127, 3090-3102	15.9	63
114	A gene signature of chemo-immunization to predict outcome in patients with triple negative breast cancer treated with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 575-575	2.2	1
113	Epstein-Barr Virus Infection of Mammary Epithelial Cells Promotes Malignant Transformation. <i>EBioMedicine</i> , 2016 , 9, 148-160	8.8	44
112	Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. <i>Nature Communications</i> , 2016 , 7, 12910	17.4	74
111	The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence. <i>JAMA Oncology</i> , 2016 , 2, 217-24	13.4	19
110	Genomic Characterization of Primary Invasive Lobular Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1872-81	2.2	175
109	Catalog of genetic progression of human cancers: breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016 , 35, 49-62	9.6	14
108	Characterization of human breast cancer tissues by infrared imaging. <i>Analyst, The</i> , 2016 , 141, 606-19	5	45
107	Tumor infiltrating lymphocytes before and after dual HER2 blockade in HER2-amplified early breast cancer: A TRYPHAENA substudy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11507-11507	2.2	2
106	Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients. <i>Clinical Genetics</i> , 2016 , 89, 336-40	4	17
105	Landscape of somatic mutations in 560 breast cancer whole-genome sequences. <i>Nature</i> , 2016 , 534, 47-54	50.4	1193
104	Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance. <i>Clinical Cancer Research</i> , 2016 , 22, 5238-5248	12.9	30
103	Evolving paradigms in multifocal breast cancer. <i>Seminars in Cancer Biology</i> , 2015 , 31, 111-8	12.7	29
102	Subclonal diversification of primary breast cancer revealed by multiregion sequencing. <i>Nature Medicine</i> , 2015 , 21, 751-9	50.5	521
101	Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells. <i>Genome Research</i> , 2015 , 25, 814-24	9.7	52
100	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. <i>BMC Medicine</i> , 2015 , 13, 177	11.4	35
99	Principles Governing A-to-I RNA Editing in the Breast Cancer Transcriptome. <i>Cell Reports</i> , 2015 , 13, 277-89	10.6	137

98	Uncovering the genomic heterogeneity of multifocal breast cancer. <i>Journal of Pathology</i> , 2015 , 236, 457-66	6.6	61
97	Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma 2015 , 3,		1
96	CCR 20th Anniversary Commentary: Gene-Expression Signature in Breast Cancer--Where Did It Start and Where Are We Now?. <i>Clinical Cancer Research</i> , 2015 , 21, 4743-6	12.9	18
95	Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1680-7	2.2	47
94	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. <i>Oncotarget</i> , 2015 , 6, 30306-16	3.3	11
93	Infrared imaging in breast cancer: automated tissue component recognition and spectral characterization of breast cancer cells as well as the tumor microenvironment. <i>Analyst, The</i> , 2014 , 139, 1044-56	5	55
92	Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes. <i>Science</i> , 2014 , 345, 1251343	33.3	250
91	Biology of breast cancer during pregnancy using genomic profiling. <i>Endocrine-Related Cancer</i> , 2014 , 21, 545-54	5.7	48
90	Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. <i>Annals of Oncology</i> , 2014 , 25, 1544-50	10.3	780
89	The technologically integrated oncosimulator: combining multiscale cancer modeling with information technology in the in silico oncology context. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2014 , 18, 840-54	7.2	29
88	Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. <i>BMC Genomics</i> , 2014 , 15, 1008	4.5	45
87	Impact of tumor sequencing on the use of anticancer drugs. <i>Current Opinion in Oncology</i> , 2014 , 26, 347-56	5.2	18
86	Informed consent, biobank research, and locality: perceptions of breast cancer patients in three European countries. <i>Journal of Empirical Research on Human Research Ethics</i> , 2014 , 9, 48-55	1.6	11
85	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. <i>Molecular Oncology</i> , 2014 , 8, 508-19	7.9	49
84	Abstract 986: Unraveling breast cancer progression through geographical and temporal sequencing 2014 ,		4
83	Genomic heterogeneity in primary breast cancer: Clinical implications.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11004-11004	2.2	1
82	Frequent BRCA1/2 and BARD1 germline mutations in triple-negative breast cancer patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1107-1107	2.2	
81	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013 , 500, 415-21	50.4	5895

80	Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients. <i>Genomics Data</i> , 2013 , 1, 7-10		3
79	Change in the microenvironment of breast cancer studied by FTIR imaging. <i>Analyst, The</i> , 2013 , 138, 4058-65		65
78	Breast cancer and melanoma cell line identification by FTIR imaging after formalin-fixation and paraffin-embedding. <i>Analyst, The</i> , 2013 , 138, 4083-91	5	39
77	Genomic grade adds prognostic value in invasive lobular carcinoma. <i>Annals of Oncology</i> , 2013 , 24, 377-384	6.3	35
76	TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer. <i>Future Oncology</i> , 2013 , 9, 1477-87	3.6	9
75	Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis. <i>PLoS ONE</i> , 2013 , 8, e62451	3.7	23
74	Abstract P2-11-02: Understanding the biology and prognosis of PIK3CA gene mutations in primary breast cancer using gene expression profiling: A pooled analysis 2013 ,		2
73	Abstract S1-05: Tumor infiltrating lymphocytes (TILs) indicate trastuzumab benefit in early-stage HER2-positive breast cancer (HER2+ BC) 2013 ,		15
72	CD4+ follicular helper T cell infiltration predicts breast cancer survival. <i>Journal of Clinical Investigation</i> , 2013 , 123, 2873-92	15.9	554
71	Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 84 Suppl 1, e58-69	7	10
70	90_PR Gene Modules and Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. A Pooled Analysis. <i>Annals of Oncology</i> , 2012 , 23, ii17	10.3	4
69	The landscape of cancer genes and mutational processes in breast cancer. <i>Nature</i> , 2012 , 486, 400-4	50.4	1264
68	Next-generation sequencing in breast cancer: first take home messages. <i>Current Opinion in Oncology</i> , 2012 , 24, 597-604	4.2	62
67	Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. <i>Oncogene</i> , 2012 , 31, 3569-83	9.2	28
66	A three-gene model to robustly identify breast cancer molecular subtypes. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 311-25	9.7	218
65	Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment. <i>Clinical Cancer Research</i> , 2012 , 18, 1004-14	12.9	39
64	Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1996-2004	2.2	167
63	HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. <i>Lancet Oncology, The</i> , 2011 , 12, 1134-42	21.7	141

62	Multiple-input multiple-output causal strategies for gene selection. <i>BMC Bioinformatics</i> , 2011 , 12, 458	3.6	2
61	Gene profiling assay and application: the predictive role in primary therapy. <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 124-7	4.8	8
60	Time to move forward from "first-generation" prognostic gene signatures in early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011 , 128, 643-5	4.4	1
59	Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response. <i>BMC Bioinformatics</i> , 2011 , 12, 310	3.6	2
58	DNA methylation profiling reveals a predominant immune component in breast cancers. <i>EMBO Molecular Medicine</i> , 2011 , 3, 726-41	12	167
57	Multifactorial approach to predicting resistance to anthracyclines. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1578-86	2.2	143
56	Low residual proliferation after short-term letrozole therapy is an early predictive marker of response in high proliferative ER-positive breast cancer. <i>Endocrine-Related Cancer</i> , 2011 , 18, 721-30	5.7	6
55	International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). <i>Journal of the National Cancer Institute Monographs</i> , 2011 , 2011, 147-51	4.8	55
54	Global microRNA expression profiling identifies MiR-210 associated with tumor proliferation, invasion and poor clinical outcome in breast cancer. <i>PLoS ONE</i> , 2011 , 6, e20980	3.7	175
53	Amplification of LPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer. <i>Nature Medicine</i> , 2010 , 16, 214-8	50.5	262
52	Discrimination between healthy and tumor tissues on formalin-fixed paraffin-embedded breast cancer samples using IR imaging. <i>Spectroscopy</i> , 2010 , 24, 67-72		20
51	210 Anthracyclines and topoisomerase II alpha ¿what is beyond?. <i>European Journal of Cancer, Supplement</i> , 2010 , 8, 120	1.6	1
50	Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials. <i>Lancet Oncology, The</i> , 2010 , 11, 358-65	21.7	97
49	Doubling back on centromere 17 in early breast cancer. <i>Lancet Oncology, The</i> , 2010 , 11, 216-7	21.7	
48	Genomic index of sensitivity to endocrine therapy for breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4111-9	2.2	203
47	A fuzzy gene expression-based computational approach improves breast cancer prognostication. <i>Genome Biology</i> , 2010 , 11, R18	18.3	36
46	Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. <i>Oncologist</i> , 2010 , 15, 246-52	5.7	40
45	Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. <i>Current Opinion in Oncology</i> , 2010 , 22, 547-51	4.2	42

44	Strategies to Incorporate Translational Research Science into Clinical Trials in Breast Cancer. <i>Current Breast Cancer Reports</i> , 2010 , 2, 208-213	0.8	
43	An advanced discrete state-discrete event multiscale simulation model of the response of a solid tumor to chemotherapy: Mimicking a clinical study. <i>Journal of Theoretical Biology</i> , 2010 , 266, 124-39	2.3	35
42	HER-2 as a target for breast cancer therapy. <i>Clinical Cancer Research</i> , 2009 , 15, 1848-52	12.9	32
41	'In silico' oncology for clinical decision making in the context of nephroblastoma. <i>Klinische Padiatrie</i> , 2009 , 221, 141-9	0.9	17
40	Genomic grade index is associated with response to chemotherapy in patients with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3185-91	2.2	153
39	Quantitation of HER2 expression or HER2:HER2 dimers and differential survival in a cohort of metastatic breast cancer patients carefully selected for trastuzumab treatment primarily by FISH. <i>Diagnostic Molecular Pathology</i> , 2009 , 18, 22-9		36
38	Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. <i>BMC Genomics</i> , 2009 , 10, 424	4.5	67
37	The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. <i>BMC Medical Genomics</i> , 2009 , 2, 40	3.7	58
36	Development and validation of gene expression profile signatures in early-stage breast cancer. <i>Cancer Investigation</i> , 2009 , 27, 1-10	2.1	19
35	A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. 2009 ,		14
34	Predicting the efficacy of anthracyclines in breast cancer (BC) patients: Results of the neoadjuvant TOP trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 523-523	2.2	10
33	A semantic grid infrastructure enabling integrated access and analysis of multilevel biomedical data in support of postgenomic clinical trials on cancer. <i>IEEE Transactions on Information Technology in Biomedicine</i> , 2008 , 12, 205-17		19
32	Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. <i>BMC Genomics</i> , 2008 , 9, 239	4.5	272
31	Comparison of prognostic gene expression signatures for breast cancer. <i>BMC Genomics</i> , 2008 , 9, 394	4.5	110
30	ACGT: A platform to facilitate future clinico-genomic research on breast cancer. <i>European Journal of Cancer, Supplement</i> , 2008 , 6, 17-18	1.6	
29	Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. <i>Breast Cancer Research</i> , 2008 , 10, R65	8.3	658
28	Erratum to [When should I start using a new biomarker: Focus on Expression arrays][EJC Supplement, 5 (2007) 97-104]. <i>European Journal of Cancer</i> , 2008 , 44, 326-328	7.5	2
27	Gene expression predictors in breast cancer: current status, limitations and perspectives. <i>European Journal of Cancer</i> , 2008 , 44, 2714-20	7.5	45

26	Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. <i>Clinical Cancer Research</i> , 2008 , 14, 5158-65	12.9	641
25	Translating multiscale cancer models into clinical trials: Simulating breast cancer tumor dynamics within the framework of the Trial of Principle Clinical trial and the ACGT project. 2008 ,		1
24	A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all?. <i>Bioinformatics</i> , 2008 , 24, 2200-8	7.2	157
23	A significant proportion of elderly patients develop hormone-dependant "luminal-B" tumours associated with aggressive characteristics. <i>Critical Reviews in Oncology/Hematology</i> , 2008 , 67, 80-92	7	46
22	Computational Intelligence in Clinical Oncology: Lessons Learned from an Analysis of a Clinical Study. <i>Studies in Computational Intelligence</i> , 2008 , 237-268	0.8	1
21	The "Oncosimulator": a multilevel, clinically oriented simulation system of tumor growth and organism response to therapeutic schemes. Towards the clinical evaluation of in silico oncology. <i>Annual International Conference of the IEEE Engineering in Medicine and Biology Society</i> , 2007 , 2007, 6629-32		19
20	Predicting risk of breast cancer recurrence using gene-expression profiling. <i>Pharmacogenomics</i> , 2007 , 8, 101-11	2.6	10
19	Estrogens decrease gamma-ray-induced senescence and maintain cell cycle progression in breast cancer cells independently of p53. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 67, 1187-200	4	11
18	p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. <i>Annals of Oncology</i> , 2007 , 18, 997-1003	10.3	45
17	Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1239-46	2.2	650
16	Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. <i>Clinical Cancer Research</i> , 2007 , 13, 3207-14	12.9	759
15	When should I start using a new biomarker: Focus on expression arrays?. <i>European Journal of Cancer, Supplement</i> , 2007 , 5, 97-104	1.6	1
14	Development and Validation of Gene Expression Profile Signatures in Early-Stage Breast Cancer. <i>Translational Medicine Series</i> , 2007 , 121-136		
13	Impact of cyclins E, neutrophil elastase and proteinase 3 expression levels on clinical outcome in primary breast cancer patients. <i>International Journal of Cancer</i> , 2006 , 119, 2539-45	7.5	37
12	Proliferation: the most prominent predictor of clinical outcome in breast cancer. <i>Cell Cycle</i> , 2006 , 5, 2198-202	4.7	67
11	Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancer. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 2572-9	6.1	67
10	Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner. <i>Molecular Cancer Therapeutics</i> , 2006 , 5, 3042-51	6.1	51
9	Gene expression profiling in breast cancer. <i>Annals of Oncology</i> , 2006 , 17 Suppl 10, x259-62	10.3	24

8	Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 262-72	9.7	1485
7	Comprehensive analysis integrating both clinicopathological and gene expression data in more than 1,500 samples: Proliferation captured by gene expression grade index appears to be the strongest prognostic factor in breast cancer (BC). <i>Journal of Clinical Oncology</i> , 2006 , 24, 507-507	2.2	6
6	Genomic and Molecular Classification of Breast Cancer 2006 , 595-621		
5	Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. <i>Clinical Cancer Research</i> , 2005 , 11, 4393-9	12.9	87
4	Breast cancer gene expression profiling: clinical trial and practice implications. <i>Pharmacogenomics</i> , 2005 , 6, 49-58	2.6	10
3	Prediction of early distant relapses on tamoxifen in early-stage breast cancer (BC): A potential tool for adjuvant aromatase inhibitor (AI) tailoring. <i>Journal of Clinical Oncology</i> , 2005 , 23, 509-509	2.2	7
2	Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1207-14	6.1	83
1	Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights. <i>British Journal of Cancer</i> ,	8.7	1